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Background: Sepsis is a major risk factor for the development of thrombocytopenia, but few studies have
specifically evaluated prognostic importance of thrombocytopenia in patients with sepsis. We investigated the
incidence, risk factors, and prognostic importance of thrombocytopenia in adult patients admitted to the
intensive care unit (ICU) with sepsis.
Methods: A retrospective analysis of patients admitted with severe sepsis/septic shock from December 2007 to
January 2009 to a 24-bed medical ICU was done.
Results: A total of 304 patients were included in the study. The patients' mean (±SD) age was 68.8 (±15.8) years.
The majority (93.7%) had septic shock, and pneumonia was the most common infection (38.8%).
Thrombocytopenia developed in 145 patients (47.6%): 77 (25.3%) at ICU admission and 68 (22.3%) during their
hospital course. The median (IQR) duration of thrombocytopenia was 4.4 (1.9–6.9) days. Patients who developed
thrombocytopenia had more episodes of major bleeding (14.4% vs. 3.7%, P < 0.01) and received more
transfusions. Patients with thrombocytopenia had a higher incidence of acute kidney injury (44.1% vs. 29.5%,
P < 0.01), prolonged vasopressor support (median (IQR): 37 (17–76) vs. 23 (13–46) h, P < 0.01), and longer ICU
stay (median (IQR): 3.1 (1.6–7.8) vs. 2.1 (1.2–4.4) days, P < 0.01). The 28-day mortality was similar between patients
with and without thrombocytopenia (32.4% vs. 24.5%, P = 0.12). However, while 15 of 86 patients (17.4%) who
resolved their thrombocytopenia died, 32 of 59 patients (54.2%) whose thrombocytopenia did not resolve died
(P < 0.01). The association between non-resolution of thrombocytopenia and mortality remained significant after
adjusting for age, APACHE III score and compliance with a sepsis resuscitation bundle (P < 0.01).
Conclusions: Thrombocytopenia is common in patients who are admitted to the ICU with severe sepsis and
septic shock. Patients with thrombocytopenia had more episodes of major bleeding, increased incidence of
acute kidney injury, and prolonged ICU stay. Non-resolution of thrombocytopenia, but not thrombocytopenia
itself, was associated with increased 28-day mortality.
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Thrombocytopenia (platelet count < 150,000/μl) is
common in critically ill patients, with an estimated
incidence of 20%–40% at some point during the in-
tensive care unit (ICU) stay [1]. Thrombocytopenia
is recognized as an independent risk factor for mortal-
ity in ICU patients [2,3]. Both the nadir platelet count
and a large drop in platelet count predict a poor
outcome in adult ICU patients [3]. Prolonged throm-
bocytopenia and absence of relative increase in the
platelet count were also associated with a greater risk
of mortality [4]. Many studies tried to identify conse-
quential risk factors for the development of throm-
bocytopenia in the ICU. Sepsis was found to be the
most common risk factor in several studies [2,5-7]. In-
creased severity of illness (as suggested by high Acute
Physiology, Age, and Chronic Health Evaluation (APA-
CHE) II and Sequential Organ Failure Assessment
(SOFA) scores) [2,8] and drugs (heparin, beta lactam an-
tibiotics, and vancomycin) [5,6] were also suggested to
be risk factors for thrombocytopenia; however, these
findings have not been consistent among various
studies.
To date, most studies focus on the incidence and risk
factors for the development of thrombocytopenia, as
well as its association with clinical outcomes in general
ICU populations. The data are limited about incidence
of thrombocytopenia and its association with clinical
outcomes in patients with severe sepsis and septic
shock. There are also limited data available about the
incidence of secondary consumptive thrombocytopenia,
like disseminated intravascular coagulation (DIC) and
thrombotic thrombocytopenic purpura (TTP) in pa-
tients with sepsis. The incidence of DIC in severe
sepsis/septic shock patients is estimated from random-
ized control trial (RCT) data evaluating the therapeutic
role of antithrombin III or immunomodulatory drugs
[9-12]. However, the data from these RCTs may be of
limited use to make epidemiological inferences because
these studies represent a highly selective population
group. There are also inconsistencies among the vari-
ous studies evaluating the risk factors for development
of thrombocytopenia [5,7]. A recent study evaluating
the incidence and risk factors for thrombocytopenia in
septic shock patients identified a higher SOFA score
(mean SOFA score of 12.7) as an independent risk fac-
tor for the development of thrombocytopenia [8]. This
finding has limited utility because one of the factors
used to calculate the SOFA score is actually the plate-
let count.
The objective of this study was to evaluate the incidence,
risk factors, and prognostic importance of thrombocy-
topenia in patients admitted to an ICU with severe sepsis
or septic shock. We also investigated the relationshipbetween thrombocytopenia and major bleeding episodes
and transfusion requirements.
Methods
This is a retrospective cohort study conducted at the
Mayo Clinic Medical Center, Rochester, MN. The study
was approved by the Institutional Review Board. In-
formed consent was waived because of the anonymous
and observational nature of this study. Adult patients
(age ≥ 18 years) admitted to the 24-bed medical ICU at
the St. Marys Hospital, Rochester, MN with a diagnosis
of severe sepsis or septic shock between December 2007
and January 2009 were included in the study. Study pa-
tients were identified from the existing Sepsis Quality
Initiative database, which contains data of patients ad-
mitted to the medical ICU with sepsis at the Mayo Med-
ical Center. Only the first admission was included for
patients who had multiple ICU admissions. Patients who
have not authorized their medical records to be reviewed
for research were excluded. Other exclusion criteria were
history of platelet disorders (e.g., idiopathic thrombo-
cytopenia purpura, congenital thrombocytopenia, hypers-
plenism), hematologic malignancies, use of chemotherapy
(in the last 30 days prior to admission), mechanical heart
valves, alcohol abuse, and hepatic cirrhosis.
The following data were abstracted from the patients’
electronic medical records: age, ethnicity, gender, co-
morbidities, stage of sepsis, compliance with institu-
tional sepsis resuscitation bundle, source of infection,
microbial organism, development of acute lung injury
(ALI) or acute respiratory distress syndrome (ARDS),
duration of mechanical ventilation, vasopressor use,
major bleeding episodes, transfusion requirements, dur-
ation of ICU stay, and 28-day mortality. The APACHE
III score and predicted mortality were abstracted from
the ICU Data Mart of our institution [13]. For patients
who developed acute kidney injury, worst risk of renal
dysfunction, injury to the kidney, failure of kidney func-
tion, loss of kidney function, and end-stage kidney dis-
ease (RIFLE) stage was determined [14]. The following
laboratory values were collected for all patients when
available: hemoglobin, creatinine, lactate, albumin, daily
platelet count (up to 14 days or death whichever hap-
pened earlier), prothrombin time, activated partial
thromboplastin time, D-dimer assay, fibrinogen level,
peripheral blood smear evidence of hemolysis, serum
lactate dehydrogenase, serum hepatic function panel,
haptoglobin, and anti-platelet factor 4-heparin antibody
by enzyme-linked immunosorbent assay (ELISA). Data
about the usage of medications that are commonly asso-
ciated with thrombocytopenia in critically ill patients
was recorded [15]. We reviewed whether the study pa-
tients received beta-lactam antibiotics, vancomycin, li-
nezolid, trimethoprim-sulfamethoxazole, H2 receptor
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low-molecular weight heparin). One-time orders and
medications prescribed ‘as needed’ were excluded.
Definitions
Thrombocytopenia was defined as having a platelet
count of <150 × 103/μL (based on the hospital labora-
tory’s reference range and from published literature)
[8,16]. If more than one platelet value is available for a
day, the lowest value was used. Severity of throm-
bocytopenia was classified into the following categories on
the basis of nadir platelet count [8]: mild 101–149 × 103/μL,
moderate 51–100 × 103/μL, severe 21–50 × 103/μL, and
very severe ≤20 × 103/μL. Severe sepsis and septic shock
were defined according to published guidelines [17].
Compliance with the institutional sepsis resuscitation
bundle was met if the patient received evidence-based
sepsis resuscitation care within 6 h as per the Surviving
Sepsis Campaign guidelines [18]. Sites of infection were
defined as per the guidelines from the International
Sepsis Forum Consensus Conference [19]. ALI and
ARDS were identified as per the American-European
Consensus Conference definition [20]. Overt DIC was
defined according to the International Society on
Thrombosis and Haemostasis (ISTH) scoring system
[21]. In case of missing data, normal values were assumed
for calculation of the DIC score. Immune-mediated,
heparin-induced thrombocytopenia (HIT) was defined
as the presence of clinical criteria suggestive of HIT and
the presence of platelet factor-4 antibodies [22]. Drug-
induced thrombocytopenia was defined according to the
published criteria as definite, probable, possible, or un-
likely [23]. Major bleeding was defined as any intracra-
nial or retroperitoneal bleed or overt bleeding (visible or
symptomatic bleeding) with a decrease of hemoglobin
concentration by more than 2 g/dL (20 g/L), or the re-
quirement for transfusion of two or more units of
packed red blood cells [24]. Multiple bleeding events
from the same bleeding site/source were counted only
once for each patient.
Definitions for co-morbidities: Hypertension was identi-
fied if patient had a known diagnosis of hypertension or
was using anti-hypertensive medications. Diabetes melli-
tus was identified if the patient’s medical record contained
an established diagnosis and use of any of the following:
oral hypoglycemic drugs, insulin, or exanetide. Chronic
lung disease was known to be present if patient’s medical
record had an established diagnosis of asthma, chronic ob-
structive pulmonary disease, cystic fibrosis or interstitial
lung disease. Coronary artery disease and congestive heart
failure were identified if the medical record documented
an established diagnosis of same. Alcohol abuse was de-
fined as a known diagnosis of chronic alcoholism, a previ-
ous admission for alcohol detoxification or alcoholwithdrawal, or reported alcohol consumption of more
than two drinks per day or >14 drinks/week [25].
Statistical analysis
Data were summarized as mean (standard deviation
(SD)), median (interquartile range (IQR)) or percentages.
We used unpaired Student’s t test to compare continuous
variables with normal distribution and Mann-Whitney U
test for skewed distribution. For comparison of categorical
variables, we used chi-square test if the number of ele-
ments in each cell were 5 or higher and Fisher’s exact test,
otherwise. Multivariate logistic regression analysis was
performed to determine independent risk factors associ-
ated with the development of thrombocytopenia. Univari-
ate analysis was done to identify the candidate variables
for multiple logistic regression analysis. Colinear vari-
able with a low P value (≤0.1) or variables that were
thought to have strong biologic associations were in-
cluded in the model. To determine the impact of
thrombocytopenia on mortality, we performed a multi-
variate logistic regression analysis using the 28-day
mortality as the dependent factor. Variables considered
for the multivariate modeling included age, APACHE
III score, and compliance with sepsis resuscitation bun-
dle. The performance of the multiple logistic regression
models were assessed by the area under the receiver
operating characteristic curve statistics. When appro-
priate, the odds ratio (OR) and 95% confidence inter-
vals (CI) were calculated. A P value of <0.05 was
considered statistically significant. The JMP statistical
software (version 8.0; SAS Institute, Inc, Cary, NC,
USA) was used for all data analyses.Results and discussion
Results
Between December 28, 2007 and January 12, 2009, 387
patients were admitted to the ICU with severe sepsis or
septic shock, of whom 83 patients were excluded from
the study due to preexisting exclusion criteria. The rea-
sons for exclusion included lack of research authorization
(14 patients), cirrhosis (20 patients), hematologic malig-
nancy (17 patients), alcoholism (15 patients), chronic
thrombocytopenic disorder (7 patients), active chemother-
apy (6 patients), and a mechanical heart valve (4 patients).
A total of 304 patients were included in the study, of
whom 171 (56.2%) were male patients. The patients’
mean (±SD) age was 68.8 (±15.8) years and majority of
them were Caucasians (269 out of 304, 88.4%). Septic
shock was present in 285 out of 304 patients (93.7%),
and the most common source of sepsis was pneumonia
(Table 1).
Thrombocytopenia developed in 145 patients (47.6%);
77 (25.3%) patients had low platelet count at the time of
Table 1 Source of sepsis for all patients admitted to ICU
(n = 304)
Source of sepsis Number of sources (%)
Pneumonia 118 (38.8)
Urinary tract 57 (18.8)
Intra-abdominal 29 (9.5)
Skin and soft tissue infection 18 (5.9)
Blood stream infection 13 (4.3)
Other sources 20 (6.6)
Unknown 49 (16.1)
ICU, intensive care unit.
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veloped thrombocytopenia during their hospital course.
The median (IQR) duration of thrombocytopenia was 4.4
(1.9–6.9) days. There were no significant differences in
the stage of sepsis and the compliance with sepsis resusci-
tation bundle for patients with thrombocytopenia as com-
pared to patients who did not develop thrombocytopenia.
Patients with thrombocytopenia had higher APACHE
III scores compared to patients who did not have
thrombocytopenia (P < 0.01) (Table 2).
Patients with thrombocytopenia had significantly ele-
vated serum lactic acid levels at ICU admission (median
value, 2.7 mmol/L vs. 1.8 mmol/L, P < 0.01). Patients with
thrombocytopenia also had elevated serum creatinine and
bilirubin levels and lower serum albumin compared to the
patients without thrombocytopenia (Table 3). There were
no statistically significant differences in serum hemo-
globin, prothrombin time, partial thromboplastin time,
and hepatic transaminase levels between these two
groups.Table 2 Demographics and clinical characteristics of 304 pati
Variable Thrombocytop
(n = 145)
Age (years), mean (SD) 69.5 (15.4)
Male gender, n (%) 85 (58.6)
White race, n (%) 129 (88.9)
Hypertension, n (%) 108 (74.4)
Diabetes, n (%) 55 (37.9)
Chronic lung disease, n (%) 36 (24.8)
Chronic kidney disease, n (%) 46 (31.7)
Coronary artery disease, n (%) 46 (31.7)
Congestive heart failure, n (%) 35 (24.1)
Septic shock, n (%) 135 (93.1)
Compliance with sepsis bundle, n (%) 62 (42.7)
APACHE III score, mean (SD) 81.7 (29.7)
Age adjusted Charlson Index, median (IQR) 5 (3–9)
ICU, intensive care unit; SD, standard deviation; APACHE, Acute Physiology, Age, anOf the 145 patients who developed thrombocytopenia,
37 (25.5%) were found to have overt DIC. Possible drug-
induced thrombocytopenia developed in 26 of 145
patients (17.9%), and all the cases were thought to be sec-
ondary to antibiotics. ELISA to detect heparin-platelet fac-
tor 4 antibodies was performed in 49 patients. Two patients
had equivocal test results but later ruled out and did not
have immune-mediated HIT. One patient had a positive
test result and was diagnosed with immune-mediated HIT
(Table 4).
Patients who developed thrombocytopenia had more
episodes of major bleeding compared to those patients
who did not develop thrombocytopenia (14.4% vs. 3.7%,
P < 0.01). Patients with thrombocytopenia also received
more blood product transfusions. Sixty-four of 145 pa-
tients with thrombocytopenia developed acute kidney in-
jury (worst RIFLE stage of ‘injury’ or more) compared to
47 of 159 patients without thrombocytopenia (P < 0.01).
Patients with thrombocytopenia received prolonged vaso-
pressor support and had longer ICU lengths of stay. ICU
mortality and 28-day mortality were not significantly dif-
ferent between these two groups (Table 5). Patients with
higher severity of thrombocytopenia had higher incidence
of ALI/ARDS. Twenty-three out of 73 patients (31.5%)
with moderate or higher severity of thrombocytopenia de-
veloped ALI or ARDS compared to 39 out of 231 patients
(16.8%) with no or mild thrombocytopenia (P < 0.01). Al-
though the mortality increased with severity of throm-
bocytopenia, it did not reach a statistical significance. The
28-day mortality was 25.5% (59 out of 231) in patients
with no or mild thrombocytopenia, compared to 37% (27
out of 73) in patients with the thrombocytopenia severity
of moderate or higher (P = 0.06).ents admitted to ICU with sepsis















d Chronic Health Evaluation; IQR, interquartile range. *Significant P values.
Table 3 Laboratory values at admission to the intensive care unit
Variable Thrombocytopenia No thrombocytopenia P value
(n = 145) (n = 159)
Hemoglobin (g/dL), mean (SD) 11.3 (2.1) 11.3 (2.2) 0.81
Albumin (g/dL), mean (SD) 2.5 (0.6) 2.8 (0.4) 0.015*
(n = 132) (n = 75) (n = 57)
Lactate (mmol/L), median (IQR) 2.7 (1.4–4.1) 1.8 (1.1–2.7) <0.0001*
(n = 299) (n = 142) (n = 157)
Creatinine (mg/dL), median (IQR) 1.6 (1.1–3.2) 1.3 (0.8–2.2) 0.002*
Total Bilirubin (mg/dL), median (IQR) 0.7 (0.4–1.3) 0.5 (0.3-0.5) 0.001*
(n = 216) (n = 116) (n = 100)
Day 1 net fluid balance (L), median (IQR) 5.1 (2.9–8.0) 4.7 (2.4-7.1) 0.16
Day 2 net fluid balance (L), median (IQR) 1.8 (0.2–3.4) 1.6 (0.2–3.4) 0.59
(n = 298) (n = 143) (n = 155)
SD, standard deviation; IQR interquartile range. SI conversion factors: to convert hemoglobin and albumin values to g/L, multiply by 10; to convert creatinine
values to μmol/L, multiply by 88.4; to convert total bilirubin values to μmol/L, multiply by 17.104. *Significant P values.
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bocytopenia according to multivariate logistic regression
analysis are shown in Table 6. Candidate variables with
significant P values in univariate analysis were entered
into the model. Elevated serum lactate and prolonged
vasopressor duration were independent risk factors for de-
velopment of thrombocytopenia, after adjusting for age
and compliance with the institutional sepsis resuscitation
bundle.
Eighty-six of 145 patients who developed thrombocy-
topenia had normal platelet count values by the time of
discharge from the hospital. Patients with persistent
thrombocytopenia had higher ICU, hospital, and 28-day




At the time of ICU admit, n (%) 77 (25.3)
During the ICU/hospital course, n (%) 68 (22.3)
Duration of thrombocytopenia (days), median (IQR) 4.4 (1.9–6.9)
Resolution of thrombocytopenia by
hospital discharge, n (%)
86 (59.3)
Severity of thrombocytopenia
Mild, n (%) 72 (49.6)
Moderate, n (%) 47 (32.4)
Severe, n (%) 19 (13.1)
Very severe, n (%) 7 (4.8)
Disseminated intravascular coagulation, n (%) 37 (25.5)
Drug-induced thrombocytopenia, n (%) 26 (17.9)
Heparin-induced thrombocytopenia, n (%) 1 (0.6)
ICU, intensive care unit; IQR, interquartile range.counts normalized during hospitalization (Table 7). Fifteen
of 86 patients (17.4%) who resolved their thrombocyto-
penia by the time of discharge from hospital died, com-
pared to 32 of 59 (54.2%) who did not resolve their
thrombocytopenia (P < 0.01). The association between
non-resolution of thrombocytopenia and 28-day mortality
remained significant after adjusting for age, APACHE III
score, and compliance with sepsis resuscitation bundle
(P < 0.01), with a receiver operating characteristic
(ROC) area under curve (AUC) of 0.78 (Figure 1).
Discussion
In this retrospective study of 304 patients admitted to
ICU with severe sepsis or septic shock, thrombocy-
topenia developed in 145 (47.6%) patients. The majority
of the patients (285 out of 304 patients, 93.7%) had sep-
tic shock, and the most common source of sepsis was
pneumonia. Patients with thrombocytopenia had higher
severity of illness scores (APACHE III) and elevated lac-
tate levels compared to the patients who did not have
thrombocytopenia. Elevated serum lactate and prolonged
vasopressor duration were found to be independent
risk factors for development of thrombocytopenia after
adjusting for age and compliance with the institutional
sepsis resuscitation bundle. Patients with thrombo-
cytopenia were more likely to develop major bleeding
episodes and to receive more blood product transfu-
sions. Patients who developed thrombocytopenia had a
higher incidence of acute kidney injury, required pro-
longed vasopressor support, and had a prolonged ICU
stay. ICU mortality and 28-day mortality were not
significantly different between these two groups. Al-
though mortality increased with the severity of thrombo-
cytopenia, the association between these two variables did
not reach a statistical significance. Of the 145 patients
Table 5 Comparison of clinical outcome data for patients with and without thrombocytopenia
Variable Thrombocytopenia No thrombocytopenia P value
(n = 145) (n = 159)
Major bleeding, n (%) 21 (14.4) 6 (3.7) 0.001*
PRBC transfusion, n (%) 85 (58.6) 62 (38.9) 0.0006*
FFP transfusion, n (%) 24 (16.5) 15 (9.4) 0.06
Platelet transfusion, n (%) 16 (11.3) 0 <0.0001*
Cryoprecipitate transfusion, n (%) 8 (5.5) 0 0.002*
Acute kidney injury (worst RIFLE stage ‘injury’ or more), n (%) 64 (44.1) 47 (29.5) 0.008*
Vasopressor duration (h), median (IQR) 37 (17–76) 23 (13–46) 0.004*
ALI/ARDS, n (%) 33 (22.8) 29 (18.2) 0.32
Mechanical ventilation, n (%) 75 (51.7) 78 (49.1) 0.64
Mechanical ventilation duration (days), median (IQR) 5.1 (2.1–9.2) 3 (1.1–9.2) 0.11
ICU length of stay (days), median (IQR) 3.1 (1.6–7.8) 2.1 (1.2–4.4) 0.001*
ICU mortality, n (%) 24 (16.5) 19 (11.9) 0.25
28-day mortality, n (%) 47 (32.4) 39 (24.5) 0.12
PRBC, packed red blood cells; FFP, fresh frozen plasma; RIFLE, risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function and
end-stage kidney disease; IQR, interquartile range; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ICU, intensive care unit. * Significant P values.
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platelet counts by the time of discharge from the hospital.
Patients who did not resolve their thrombocytopenia by
the time of hospital discharge had higher mortality com-
pared to those patients whose platelet counts were nor-
malized by the time of hospital discharge. The association
between non-resolution of thrombocytopenia and 28-day
mortality remained significant after adjusting for age,
APACHE III score, and compliance with sepsis resuscita-
tion bundle.
The incidence of thrombocytopenia was 47.6% in our
study patients. Previous studies that specifically evalu-
ated thrombocytopenia in patients with infection re-
ported an incidence of 22%–58% [8,26-29]. This wide
variation in incidence of thrombocytopenia is likely ex-
plained by the disparate characteristics of these studyTable 6 Multivariate logistic regression model analyzing
various risk factors for development of






APACHE III score 0.99 0.98–1.02 0.9
Lactate 1.59 1.1–2.47 0.02*
Albumin 0.66 0.25–1.74 0.4
Creatinine 1.07 0.78–1.51 0.6
Vasopressor duration 1.02 1.00–1.03 0.02*
Acute kidney injury
(RIFLE stage ‘injury’ or more)
1.43 0.47–4.31 0.5
ICU, intensive care unit; APACHE, Acute Physiology, Age, and Chronic Health
Evaluation; RIFLE, risk of renal dysfunction, injury to the kidney, failure of
kidney function, loss of kidney function and end-stage kidney disease.
*Significant P values.patients, as well as differences in how thrombocytopenia
was defined. Gafter-Gvili et al. reported an incidence of
thrombocytopenia of 22.3% in patients with Staphylococ-
cus aureus bacteremia; however, only 11% of their patients
had septic shock [26]. In our study, 94% of patients were
diagnosed with septic shock. Other studies that included
more severely ill patients reported an incidence of throm-
bocytopenia comparable to our findings. In a study of pa-
tients with septic shock, 55% developed thrombocytopenia
[8], and another study evaluating thrombocytopenia in ICU
patients with nosocomial blood stream infections reported
an incidence of 43% [29]. When thrombocytopenia was
defined as a platelet count of <100 × 103/μL, the incidence
was reported to be about 33%–36% [28,29]. We defined
thrombocytopenia as platelet count <150 × 103/μL, which
could explain the higher incidence of thrombocytopenia
in our study.
The development of thrombocytopenia in patients with
sepsis is secondary to various mechanisms. Platelets are
activated in sepsis and bound to the endothelium, result-
ing in sequestration and destruction [30,31]. Immune-
mediated mechanisms like nonspecific platelet-associated
antibodies [32] and cytokine-driven hemophagocytosis of
platelets [33,34] can also contribute to sepsis-induced
thrombocytopenia. Severe sepsis is commonly associated
with a net procoagulant state, and secondary consumptive
conditions of thrombocytopenia, like DIC, represent an
extreme in the continuum of hemostatic abnormalities in
patients with sepsis. In our study, 25% of patients with
thrombocytopenia had overt DIC. This number is similar
to earlier reports which estimated that 15%–30% of pa-
tients with severe sepsis and septic shock develop DIC
[35]. Although DIC is considered to be a predictor of






(N = 86) (N = 59)
ICU mortality, n (%) 4 (4.6) 20 (33.9) <0.0001*
Hospital mortality, n (%) 15 (17.4) 24 (40.6) 0.002*
28-day mortality, n (%) 15 (17.4) 32 (54.2) <0.0001*
Stratified according to the resolution of thrombocytopenia by the time of hospital discharge. ICU, intensive care unit. *Significant P values.
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ence of overt DIC and mortality in our study. Immune-
mediated HIT was diagnosed in only one patient in our
study cohort. Although sepsis is not a known risk factor
for TTP, recent reports have suggested that infections can
trigger TTP in patients with preexisting risk factors
[36,37]. We did not find any case of TTP in our study.
Many studies tried to identify potential risk factors for
the development of thrombocytopenia in the ICU. Sepsis
was found to be the most common risk factor in several
studies [2,5-7]. Increased severity of illness (as suggested
by high APACHE II and SOFA scores) [2,8], presence of
invasive vascular catheters (e.g., central venous catheter,
pulmonary artery catheter) [6,7] and drugs (heparin,
beta-lactam antibiotics, and vancomycin) [5,6] were also
suggested to be risk factors for the development of throm-
bocytopenia; however, these findings have not been con-
sistent among different studies. We found that elevated
serum lactate and prolonged vasopressor duration were
independent risk factors for thrombocytopenia. It isArea under curve = 0.78
Figure 1 Receiver-operator characteristic curve analysis
showing non-resolution of thrombocytopenia as a predictor of
28-day mortality.plausible that these risk factors reflect the severity of
underlying septic process and critical illness rather
than predicting the causality. We did not specifically
evaluate for effects of specific drugs on the develop-
ment of thrombocytopenia in our patient cohort.
One of the main concerns for critically ill patients with
thrombocytopenia is bleeding. We found that patients
with thrombocytopenia were more likely to develop major
bleeding episodes and they also received more blood
product transfusions. Blood product transfusion is a risk
factor for the development of lung injury including
transfusion-associated acute lung injury (TRALI). Patients
with higher severity of thrombocytopenia had more major
bleeding episodes and they also had a higher incidence of
ALI or ARDS. We found that patients with thrombo-
cytopenia had a higher incidence of acute kidney injury
and required vasopressor support for longer duration
compared to the patients without thrombocytopenia. This
may explain the observed longer ICU length of stay for
patients with thrombocytopenia in our study.
Thrombocytopenia is a known negative prognostic in-
dicator for adverse clinical outcomes in ICU patients.
Previous studies have reported that thrombocytopenia
carries an independent risk for mortality in ICU patients
[3,4,38]. However, in our study, we did not find a signifi-
cant difference in the ICU mortality or 28-day mortality
between the patients with and without thrombocy-
topenia. This could be due to differences in the study
population, as our study included only patients with se-
vere sepsis/septic shock, whereas previous studies in-
cluded critically ill patients from both medical and
surgical ICUs. In another study of 145 critically patients
from a medical ICU, Strauss and colleagues also found
that thrombocytopenia alone was not a predictor of
mortality. A drop in platelet count of ≥30%, not throm-
bocytopenia per se predicted ICU mortality in their
study [16]. Our study results also differ from that of a
recent study by Sharma et al., who reported that throm-
bocytopenia is a predictor of mortality in patients with
septic shock [8]. Although they found that the un-
adjusted 6-month mortality rate was higher in patients
with thrombocytopenia, the receiver operator character-
istic curve analysis showed that thrombocytopenia has
poor sensitivity as a marker for predicting mortality. The
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mortality for patients with thrombocytopenia also had
wide confidence intervals in their study, thereby minim-
izing the effect size. Brogly and colleagues reported that
a platelet count of <150 × 109/L did not predict mortality
in patients admitted to ICU for severe community-
acquired pneumonia [39]. However, the ICU mortality has
increased significantly with severity of thrombocytopenia
in their study, with an initial platelet count ≤50 × 109/L
independently predicting the ICU mortality. It is plaus-
ible that severity of thrombocytopenia could be a better
predictor of mortality rather than mere presence of
thrombocytopenia.
We found that non-resolution of thrombocytopenia
during the recovery from critical illness is a strong pre-
dictor of mortality. Patients with persistent thrombo-
cytopenia had higher ICU, hospital, and 28-day mortality
compared to those patients whose platelet counts have
normalized. This association remained significant after
adjusting for age, APACHE III score, and compliance with
sepsis resuscitation bundle. An acute decrease in platelet
counts secondary to a major inflammatory event is com-
monly followed by thrombocytosis reflecting bone marrow
activation. Lack of this biphasic response of platelet reco-
very portends poor outcomes. Akca and colleagues [4]
found that a prolonged thrombocytopenia and an absence
of relative increase (a 25% increase above the admission
value) in platelet count were associated with mortality in
critically ill patients. The absence of relative increase in
the platelet count on day 14 was associated with mortality
even in patients without thrombocytopenia. Similar find-
ings were reported by Nijsten and colleagues in a group of
surgical ICU patients [40]. Our results support the find-
ings from the abovementioned studies that have shown
that changes in platelet counts over time may have greater
prognostic significance rather than the absolute counts in
critically ill patients. Our results suggest that even in pa-
tients who survived the acute illness from severe sepsis/
septic shock and discharged from ICU, lack of resolution
of thrombocytopenia portends a bad prognosis.
Care of sepsis patients has improved significantly in the
last decade with the implementation of sepsis resuscita-
tion ‘bundles’, which led to improved clinical outcomes.
It is unknown whether the prognostic significance of
thrombocytopenia has changed with the advances in the
care of sepsis patients in the ICU. We have included
compliance with sepsis resuscitation bundle as one of
the variables in our statistical analyses, and adjusted its
effect on determining the association between throm-
bocytopenia and mortality. The association between
non-resolution of thrombocytopenia and 28-day mortality
remained significant even after adjusting for the compli-
ance with sepsis resuscitation bundle. This finding is sig-
nificant because lack of resolution of thrombocytopeniastill holds an important prognostic value despite recent
advances in sepsis care.
Our study has several limitations. Since it is a retro-
spective study, we could not control for all confounding
factors that could have been present in the critically ill pa-
tients at different times. Compliance with a sepsis resusci-
tation bundle is an important factor that affects mortality
in patients with severe sepsis or septic shock. Previous
studies evaluating thrombocytopenia in septic shock pa-
tients [8] did not adjust for this important confounding
factor. Our study results were adjusted for compliance
with sepsis resuscitation bundle, which strengthens the
study findings. Although we included 304 patients in our
study, mortality rate in our study is relatively low com-
pared to other studies. Because of the relatively low num-
ber of deaths, our analyses are not adequately powered to
determine statistically significant differences between
groups. Our sample size was also not sufficient enough to
analyze the incidence or impact of rare events like
heparin-induced thrombocytopenia, etc.Conclusions
In conclusion, this is the largest study evaluating the in-
cidence and clinical outcomes of thrombocytopenia in
patients admitted to the ICU with severe sepsis and sep-
tic shock. Thrombocytopenia is common among patients
with sepsis admitted to the ICU and has prognostic im-
portance. Patients with thrombocytopenia tend to be
sicker and are more likely to develop major bleeding epi-
sodes. Although our results did not find an association
between presence of thrombocytopenia and 28-day mor-
tality, patients with thrombocytopenia had significant
morbidity as evidenced by higher incidence of acute kid-
ney injury and longer ICU stay, compared to the patients
who did not develop thrombocytopenia. Among patients
who developed thrombocytopenia, non-resolution of throm-
bocytopenia was associated with increased mortality. The
association between non-resolution of thrombocytopenia
and 28-day mortality remained significant after adjusting
for age, APACHE III score, and compliance with sepsis re-
suscitation bundle.
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